Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S; Medical Board of the National Psoriasis Foundation.

J Am Acad Dermatol. 2014 Jan;70(1):178-86. doi: 10.1016/j.jaad.2013.08.049. Epub 2013 Nov 9.

PMID:
24220724
[PubMed - indexed for MEDLINE]
2.

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.

Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.

Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.

PMID:
21719446
[PubMed - indexed for MEDLINE]
3.

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management.

Abramson A, Menter A, Perrillo R.

J Am Acad Dermatol. 2012 Dec;67(6):1349-61. doi: 10.1016/j.jaad.2012.04.036. Epub 2012 Jun 21. Review.

PMID:
22727462
[PubMed - indexed for MEDLINE]
4.

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R.

Arthritis Res Ther. 2009;11(6):R179. doi: 10.1186/ar2868. Epub 2009 Nov 26.

PMID:
19941642
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Hepatitis B core IgM antibody (anti-HBcIgM) among hepatitis B surface antigen (HBsAg) negative blood donors in Nigeria.

Japhet MO, Adesina OA, Donbraye E, Adewumi MO.

Virol J. 2011 Nov 10;8:513. doi: 10.1186/1743-422X-8-513.

PMID:
22074048
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.

Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS.

J Rheumatol. 2010 Feb;37(2):346-50. doi: 10.3899/jrheum.090436. Epub 2009 Dec 15.

PMID:
20008922
[PubMed - indexed for MEDLINE]
7.

Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.

Stine JG, Bass M, Ibrahim D, Khokhar OS, Lewis JH.

South Med J. 2011 Dec;104(12):781-8. doi: 10.1097/SMJ.0b013e318238b608.

PMID:
22089354
[PubMed - indexed for MEDLINE]
8.

Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.

Yaşar DG, Suyanı E, Özenirler S, Sucak GT.

Transplant Proc. 2013 Mar;45(2):833-4. doi: 10.1016/j.transproceed.2012.06.082.

PMID:
23498831
[PubMed - indexed for MEDLINE]
9.

Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.

Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):285-9.

PMID:
21880218
[PubMed - indexed for MEDLINE]
10.

Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.

Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM.

Am J Gastroenterol. 1996 Nov;91(11):2323-8.

PMID:
8931411
[PubMed - indexed for MEDLINE]
11.

Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B.

Bernard F, Raymond G, Willems B, Villeneuve JP.

J Viral Hepat. 1997 Jul;4(4):265-72.

PMID:
9278224
[PubMed - indexed for MEDLINE]
12.

Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.

Chung SJ, Kim JK, Park MC, Park YB, Lee SK.

J Rheumatol. 2009 Nov;36(11):2416-20. doi: 10.3899/jrheum.081324. Epub 2009 Oct 1. Erratum in: J Rheumatol. 2010 Jan;37(1):216.

PMID:
19797507
[PubMed - indexed for MEDLINE]
13.

From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS.

J Am Acad Dermatol. 2013 Dec;69(6):1003-13. doi: 10.1016/j.jaad.2013.06.046. Epub 2013 Sep 26. Review.

PMID:
24075223
[PubMed - indexed for MEDLINE]
14.

Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection.

Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeb A.

Indian J Med Res. 2006 Jan;123(1):37-42.

PMID:
16567866
[PubMed - indexed for MEDLINE]
15.

Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea.

Sanders RC, Lewis D, Dyke T, Alpers MP.

P N G Med J. 1992 Sep;35(3):197-201.

PMID:
1296422
[PubMed - indexed for MEDLINE]
16.

Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?

Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY.

Transfusion. 2012 Feb;52(2):440-6. doi: 10.1111/j.1537-2995.2011.03283.x. Epub 2011 Aug 2.

PMID:
21810101
[PubMed - indexed for MEDLINE]
17.

Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.

Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H.

Liver Int. 2005 Dec;25(6):1169-74.

PMID:
16343068
[PubMed - indexed for MEDLINE]
18.

Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.

Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.

J Clin Gastroenterol. 2009 May-Jun;43(5):496-8. doi: 10.1097/MCG.0b013e3181945942.

PMID:
19247200
[PubMed - indexed for MEDLINE]
19.

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation.

J Am Acad Dermatol. 2008 Aug;59(2):209-17. doi: 10.1016/j.jaad.2008.03.023. Epub 2008 May 15.

PMID:
18485527
[PubMed - indexed for MEDLINE]
20.

Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.

Lee YH, Bae SC, Song GG.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21. Epub 2012 Oct 30. Review.

PMID:
23111095
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk